Sitagliptin is an innovative active ingredient that has transformed the treatment of type 2 diabetes. It belongs to the class of DPP-4 inhibitors and acts specifically on insulin and glucagon levels, contributing to more effective glycemic control in diabetic patients.
Uses of Sitagliptin
Sitagliptin improves glycemic control in patients with type 2 diabetes mellitus, often in combination with other hypoglycemic drugs. It is not indicated for type 1 diabetes or for treating diabetic ketoacidosis. Its primary function is to help stabilize blood sugar levels by inhibiting the DPP-4 enzyme (dipeptidyl peptidase-4) without significantly increasing the risk of hypoglycemia.
The DPP-4 enzyme is responsible for breaking down incretin hormones like GLP-1 and GIP. These hormones play a crucial role in glucose metabolism, stimulating insulin secretion when blood sugar levels are high and reducing glucagon production. By inhibiting DPP-4, Sitagliptin prolongs the activity of incretin hormones, promoting an adequate insulin response and controlling glycemic spikes.
Sitagliptin and Metformin: differences and similarities
While Sitagliptin and Metformin share the goal of improving glycemic control, their mechanisms of action are entirely different. Metformin primarily works by reducing glucose production in the liver and improving its utilization in peripheral tissues, whereas Sitagliptin regulates the activity of incretin hormones to optimize insulin response.
In many cases, the two drugs are combined to maximize therapeutic benefits. Metformin addresses insulin resistance, while Sitagliptin targets the mechanisms of insulin secretion, offering a synergistic approach to treating type 2 diabetes.
Sitagliptin and weight loss
As with other diabetes drugs, there are misconceptions regarding Sitagliptin’s potential for promoting weight loss. While it does not cause weight gain, Sitagliptin is not a weight-loss medication. Its action is aimed at glycemic control and does not directly affect fat metabolism or appetite, unlike other drugs such as GLP-1 agonists. It is important for patients to understand this aspect and always consult a doctor.
Flarer’s commitment to distributing antidiabetics
At Flarer, we believe that pharmaceutical innovation is key to improving quality of life. For this reason, we are committed to providing pharmaceutical companies with access to high-quality active ingredients such as EP/CEP grade Sitagliptin, offering reliable and safe solutions.
Thanks to our global network of suppliers, we ensure distribution that complies with international standards, contributing to the progress of solutions for diabetes management. Contact our experts for personalized advice.